Post-Approval Study of the GORE® VIABAHN® Endoprosthesis for Treatment of In-Stent Restenosis in the Superficial Femoral Artery.

Potential subjects must meet all of the following clinical inclusion criteria:
1. Patient is >= 18 years old at the time of informed consent signature
2. Patient is willing to give written informed consent
3. Patient has a previously implanted (>30 days) non-covered stent(s) located in the superficial femoral artery
4. Patient has life-style limiting claudication, resting leg pain or minor tissue loss (Rutherford category 2-5)
5. Patient demonstrates an ABI <= 0.9. If ABI > 0.9 or not measureable, patient is eligible for study if toe-brachial index (TBI) is <= 0.5
6. Patient is male, infertile female or female of childbearing potential with a negative beta human chorionic gonadotrophin (hCG) pregnancy test within 7 days of the index procedure
7. Patient is capable of complying with protocol requirements, including follow-up visits;Potential subjects must meet all of the following angiographic inclusion criteria:
1. Patient has >= 50% in-stent restenosis and/or an occlusion in a previously implanted (>30 days) non-covered stent(s) located in the superficial femoral artery defined as beginning at least 1 cm below the origin of the profunda femoris artery and ending at least 1 cm above the intercondylar notch
2. Patient has a maximum total lesion length of 270 mm, consisting of in-stent and adjacent occlusive disease
3. Patient has a minimum of 1 cm of non-stenosed vessel both proximal and distal to the target lesion(s)
4. Patient has a reference vessel diameter between 4.0 and 6.5 mm
5. The guidewire and delivery system must cross the target lesion(s) intraluminally
6. Patient has a patent popliteal artery (<50% stenosis) distal to the target vessel
7. Patient has at least 1 patent infrapopliteal runoff vessel (<50% stenosis) not requiring intervention
8. Angioplasty balloon can be fully expanded in the target lesion during pre-treatment step

Potential subjects will not be eligible for study participation if they meet any of the following clinical exclusion criteria:
1. Patient has a known allergy to stent graft components (nickel-titanium or ePTFE)
2. Patient has known allergy to contrast media that cannot be adequately pre-medicated prior to the study procedure
3. Patient with known hypersensitivity to heparin, including those patients who have had a previous incidence of heparin-induced thrombocytopenia (HIT) type II
4. Patient has a known intolerance to anticoagulation or antiplatelet therapy
5. Patient has an uncorrected bleeding disorder (platelet count <80,000/µL)
6. Patient has any known coagulation disorder, including hypercoagulability
7. Patient has severe chronic renal insufficiency (creatinine level >= 2.5mg/dL) within 30 days prior to study procedure unless currently on hemodialysis
8. Patient has septicemia or uncontrolled infection
9. Patient has any planned surgical intervention/procedure within 30 days of the study procedure
10. Patient has major distal amputation (above the transmetatarsals) in the study or non-study limb
11. Patient has prior ipsilateral femoral artery bypass
12. Patient has severe medical comorbidities (untreated coronary artery disease (CAD)/congestive heart failure (CHF), severe chronic obstructive pulmonary disease (COPD), metastatic malignancy, dementia, etc) or other medical condition that would preclude compliance with the study protocol or 3-year life expectancy
13. Patient has severe ipsilateral common or deep femoral disease requiring intervention
14. Patient has any previous surgery in the target vessel
15. Patient has had vascular access via the lower extremities within 30 days of the index procedure
16. Patient has had previous target vessel in-stent restenosis treated by relining with another stent
17. Patient is currently participating in another clinical research trial, unless approved by Sponsor;Potential subjects will not be eligible for study participation if they meet any of the following angiographic exclusion criteria:
1. Patient has untreated flow-limiting aortoiliac stenotic disease
2. Patient has an aneurysm adjacent to the target lesion(s)
3. Patient has perioperative unsuccessful ipsilateral percutaneous vascular procedure to treat inflow prior to enrollment during the index study procedure
4. Patient has femoral or popliteal aneurysm located in the target vessel
5. Patient has non-atherosclerotic disease resulting in occlusion (e.g. embolism, Buerger*s disease, vasculitis)
6. Patient has angiographic evidence of intra-arterial thrombus or atheroembolism from inflow treatment
7. Patient has target lesion access not performed by transfemoral approach